RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them
without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma.
PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating
patients who have non-Hodgkin's lymphoma that has not responded to previous treatment.